Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OGT | O15294 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674240 | 0.80 | P2RX7 (0.41) | MCL1KDM4EGRM5 | |
| SCHEMBL32674516 | 0.78 | DDB1 (0.43) | NPC1L3MBTL1 | |
| SCHEMBL32674513 | 0.72 | RAB9A (0.46) | HPGDNPC1KDM4EALDH1A1MAPT | |
| SCHEMBL32674298 | 0.72 | CRBN (0.36) | ALDH1A1 | |
| SCHEMBL32674279 | 0.70 | CYP19A1 (0.46) | NPC1RAB9A | |
| SCHEMBL32674477 | 0.68 | MCL1 (0.39) | MCL1GRM5 | |
| SCHEMBL32674293 | 0.67 | MCL1 (0.46) | MCL1KDM4EALDH1A1OGTGRM5 | |
| SCHEMBL32674491 | 0.67 | MCL1 (0.42) | MCL1OGTGRM5 | |
| SCHEMBL4409289 | 0.65 | HPGD (0.55) | HPGDNPC1KDM4EMAPTRAB9A | |
| SCHEMBL512253 | 0.62 | HPGD (0.63) | HPGDNPC1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | TRIANA BIOMEDICINES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | ALK, NTRK1, NTRK3 | HPGD 4871/4885MCL1 79/4885NPC1 619/4885 |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | ALK, NTRK3, NTRK1 | HPGD 4789/4885MCL1 223/4885NPC1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.